Led by Mt Sinai Alzheimer’s researcher and thought leader Mary Sano, PhD, and coordinated by the ADCS, the HBA study compared feasibility and efficiency, and ability to capture change over time using in-home instruments, and ability to predict cognitive conversion using pre-defined triggers in a randomized clinical trial.
“Young Latino’s Working in Alzheimer’s” Airs Tonight on UCSD TV and is Streaming on the Brain Channel
Watch a Brain Channel round table about educating, training, mentoring and funding young Latino Alzheimer’s scientists.
What’s next in the Raskind/Peskind Prazosin research? They are directing the ADCS’ Peace AD trial which will test Prazosin, as a treatment for disruptive agitation, in people with moderate to severe Alzheimer’s disease. The trial is launching this spring in over 20 memory and long term care communities in the US.
The updated guidelines reflect increased MCI research, the significance of MCI in clinical practice, and therapeutics in trials.
Rand Report: Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer’s Treatment
Link to the report home page, summary, and PDFs of the full report.
Disclosing Amyloid Status in an Alzheimer’s Prevention Trials – First A4 Study Disclosure Results Published in JAMA Neurology
From the accompanying JAMA Neurology editorial “What is clear is that, with the advance of molecular diagnostic tools in neurology, clinicians and investigators will increasingly be faced with the challenge of presenting patients with information of uncertain prognostic significance. The investigators of the A4 study are to be commended for developing a thoughtful process of…
Alan Levey, MD, PhD, Director of Emory’s Alzheimer’s Disease Research Center, commented on the findings making news: “We were amazed to see the accumulation of LSD1 in neurofibrillary tangles in Alzheimer’s, and in TDP-43 aggregates in FTD” (Published in Nature Communications this week)
Axovant’s interpirdine fails to meet the trial’s primary endpoints. Read the Alzheimer’s Forum interpirdine report
What potential therapy reports out next? There are not a lot of large, late stage, Alzheimer’s trial results expected until 2019 (including Biogen’s aducanumab, Merck’s BACE- oriented verubecestat, and Lilly/AstraZeneca’s lanabecestat).
“Our results demonstrate that ApoE affects tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-β pathology. ApoE4 exerts a ‘toxic’ gain of function whereas the absence of ApoE is protective” David Holtzman, MD Washington University
NYU’s EXERT Study Principal Investigator Martin Sadowski, MD, PhD wants to be able to write a prescription for exercise
Dr Sadowski talks about the potential of the EXERT Study to help identify the right dose of exercise to offset memory loss for people at risk for Alzheimer’s disease
Biohaven and Alzheimer’s Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate AD.
The Biohaven Pharmaceutical Holding Company Ltd. announced today its clinical trial collaboration with the Alzheimer’s Disease Cooperative Study (ADCS).
A family with an astonishing rate of Alzheimer’s disease may harbor a powerful new gene.
JAMA Neurology reports on the differences in carriers of the “most potent genetic risk factor for Alzheimer’s disease” – the apolipoprotein E ε4 (APOE4) allele.
Presented, the Fiscal Year 2019 NIH Professional Judgment Budget for Alzheimer’s Disease and Related Dementias. Outlined at the July 28 meeting of the HHS Secretary’s Advisory Council on Alzheimer’s Research, Care, and Services.